Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 23, 2024

While the year saw an overall decline in M&A activity (down 17% from 2022) , total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. Why did life sciences outperform the market? The last quarter of the year ended with a surge of deal activity.

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52

Peak Frameworks

SEPTEMBER 19, 2023

For example, in the 2012 Facebook IPO, common shareholders gained exposure to the tech giant's fortunes, while also securing a say in corporate matters. By virtue of their ownership, they possess a direct financial interest in the company's success.

Corporation 52

Corporation Private Equity Mergers and Acquisitions Corporate Finance 52

Mergers and Inquisitions

NOVEMBER 1, 2023

Advanced Financial Modeling : There’s a case study on Jazz Pharmaceuticals if you’re more interested in that vertical. What about when the IPO market is shut down and exits look uncertain? Life science-oriented roles in VC and growth firms will also be fine because there’s always demand for new biotech and pharmaceutical products.

Private Equity 59

Private Equity Healthcare Equities Middle Market 59

M&A Leadership Council

JUNE 12, 2023

She has more than 16 years of C-level experience as a security and privacy consultant, strategist and systems implementer for large institutions in the financial services, insurance, health care and pharmaceuticals sectors. Prior to joining M&A Partners, Mark headed Innovation, Research & Development for U.S.

IT 52

IT M&A Securities Insurance 52

M&A Leadership Council

AUGUST 15, 2022

For example, in Switzerland, Sandoz and Ciba spun off their chemicals business units – one as a taxable initial public offering and one as a tax-free “demerger” – before merging their pharmaceutical cores into Novartis. If the parent retains an interest in an IPO carve-out, this may be termed a “divestiture IPO.”.

Mergers and Acquisitions 52

Mergers and Acquisitions IPO M&A Initial Public Offering 52

M&A Leadership Council

SEPTEMBER 9, 2021

She has more than 16 years of C-level experience as a security and privacy consultant, strategist and systems implementer for large institutions in the financial services, insurance, health care and pharmaceuticals sectors. Prior to joining M&A Partners, Mr. Dickelman headed Innovation, Research & Development for U.S.

IT 52

IT M&A Securities Insurance 52